GRAIL, Inc. Common Stock

Day range

$132.75 – $141.68

Open

$134.83

Prev close

$132.55

Volume

411.15K

Market cap

$5.92B

Shares out

44.67M

P/E

—

P/S

35.82

P/B

2.33

P/FCF

—

ROE

-15.4%

ROA

-13.8%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Annual meeting resultsJun 22, 2026

  The Annual Meeting of Stockholders of GRAIL, Inc. was held on June 18, 2026. The Company's stockholders elected two Class II Directors to serve until the Annual Meeting of Stockholder to be held in 2029. Sarah Krevans received 18,929,398 votes for and 2,972,804 withheld; Steven Mizell received 16,998,081 votes for and 4,904,121 withheld.

• Executive compensation changeJun 1, 2026

  The Amended Offer Letter provides that Dr. Ofman will receive an annual base salary initially set at $800,000 and will continue to be eligible to participate in the Company's Variable Compensation Plan (the "VCP"), with a target, from and after the Effective Date, equal to 100% of his annual base salary... As soon as reasonably practicable following the Effective Date, the Company will grant Dr. Ofman an award of restricted stock units ("RSUs") with an aggregate grant date value of $2,000,000, vesting in equal annual installments on each of the first four anniversaries of May 31, 2026.

• Clinical trial resultsFeb 19, 2026

  On February 19, 2026, the Company also issued a press release announcing top-line results from its NHS-Galleri trial, a randomized controlled trial conducted in partnership with NHS England, showing that, although the primary endpoint of statistically significant Stage III-IV reduction was not observed, adding Galleri to standard of care screening resulted in a substantial reduction in Stage IV cancer diagnoses, increased Stage I and II detection of deadly cancers, and four-fold higher cancer detection rate when compared to standard of care alone.

• Investor presentationJan 12, 2026

  On January 12, 2026, GRAIL, Inc. (the "Company") plans to present a corporate update and preliminary financial information for the quarter and year ended December 31, 2025 at the 2026 J.P. Morgan Healthcare Conference. A copy of the presentation that will be used is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

• Underwriting agreementNov 14, 2025

  The Company entered into an Equity Distribution Agreement with Morgan Stanley & Co. LLC and TD Securities (USA) LLC, as sales agents and/or principals. The Sales Agents will use commercially reasonable efforts to sell the common stock from time to time, and the Company will pay the Sales Agents a commission equal up to 3.0% of the aggregate of the gross sales proceeds.

Days to cover

4.1

Short interest

8.01M

Avg volume

1.93M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.
  neutralThe Motley Fool· Oct 11, 2026
• 3 Reasons to Buy Grail (GRAL) Hand Over Fist in October
  positiveThe Motley Fool· Sep 30, 2026
• PICS FINAL DEADLINE ALERT: PicS N.V. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before August 4, 2026 Deadline – Hagens Berman
  negativeGlobeNewswire Inc.· Aug 3, 2026
• GRAL FINAL DEADLINE ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline
  negativeGlobeNewswire Inc.· Aug 3, 2026
• ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
  negativeGlobeNewswire Inc.· Aug 1, 2026